A 41.9-percentage-point placebo-adjusted EASI-75 response is not a modest signal — it is the kind of number that forces a direct comparison with dupilumab’s pivotal data, and that comparison is exactly what Apogee is inviting. In the APEX Part B induction readout, 65.9% of patients on mid-dose zumilokibart hit EASI-75 at 16 weeks against a 23.4% placebo rate, with every secondary endpoint clearing statistical significance at p<0.001 or better. The trial enrolled 346 adults randomized across three active doses and placebo, and the mid-dose emerged as the clear selection not because it outperformed the high dose on efficacy — the two were numerically comparable — but because it carried a meaningfully lower conjunctivitis rate: 10.6% versus 20.7% for the high dose. That safety-driven dose selection is itself a design signal worth noting.

The vLDA endpoint — EASI-90 plus an itch NRS of 0 or 1, simultaneously — landed at 20.6% on mid-dose versus 4.5% on placebo. That composite threshold is stringent, and no approved biologic has cleared it in a controlled induction trial at this rate. The itch data specifically matters here: 50.5% of mid-dose patients achieved an I-NRS reduction of four or more points, compared with 13.9% on placebo. Itch is notoriously difficult to move, and IL-13 selective blockade has historically underperformed dual IL-4/IL-13 inhibition on that axis. These numbers challenge that assumption directly, though a head-to-head trial remains the only way to settle the argument definitively.

The dosing schedule architecture is also clinically consequential. Part B induction required four injection days over 16 weeks; the current standard of care requires nine. Part A maintenance data, already in hand, showed sustained and even deepening efficacy on every-three-to-six-month dosing. Together, that profile creates a practical differentiation argument that a prescriber can make without waiting for a randomized comparison — fewer clinic visits, no weekly injections, durable control. Apogee is targeting Phase 3 initiation in the second half of 2026, with Phase 2 studies in eosinophilic esophagitis and asthma to follow, positioning zumilokibart as a single molecule across three large indications.

The one number that will define whether this Phase 2 translates is the Phase 3 EASI-75 replication rate at the mid-dose. Phase 2 AD trials routinely post higher responder rates than their pivotal successors due to enriched populations and investigator enthusiasm; if the 65.9% figure contracts materially in a broader Phase 3 enrollment, the competitive story weakens considerably. That replication rate — not the Blackstone financing, not the pipeline expansion — is the determinant of whether zumilokibart earns a real place in the IL-13 market.

Source link: https://www.globenewswire.com/news-release/2026/05/27/3301719/0/en/Apogee-Therapeutics-Announces-Positive-16-Week-Part-B-Induction-Dose-Optimization-Results-from-Phase-2-APEX-Trial-of-Zumilokibart-in-Moderate-to-Severe-Atopic-Dermatitis.html

+ posts

Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.